NCT04511923View on ClinicalTrials.gov

Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 23, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

February 28, 2022

Conditions
Covid19ARDS, HumanLung Injury, AcuteVentilation Perfusion Mismatch
Interventions
DRUG

Nebulised heparin

Nebulised unfractionated heparin 25000 units administered 6 hourly for 10 days

Trial Locations (1)

Unknown

University Hospital Galway, Galway

All Listed Sponsors
lead

University College Hospital Galway

OTHER

NCT04511923 - Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury | Biotech Hunter | Biotech Hunter